What I'd say if a friend asked me about compounded GLP-1 right now

A friend in San Francisco texted me last week. She's been paying $179 a month for compounded tirzepatide through Henry Meds for about eight months. Down 31 pounds, feels great, says it's the first thing in her life that's actually worked for weight. She'd seen something on Instagram about the FDA cracking down on compounded GLP-1 and wanted to know if she needed to do anything.

The honest answer is: yes, sort of, but you have a runway.

Here's what's happening. The FDA filed a proposal on April 30 to formally exclude tirzepatide from what's called the 503B bulks list. (The proposal is here if you want to read it.) That sounds like dry regulatory language. What it actually means is that the legal foundation under most compounded tirzepatide is being knocked out. The comment period closes June 29. The final rule probably lands sometime in Q3 2026.

What that means for my friend specifically: her current supply is intact. Henry Meds is still shipping. They have not announced a pivot to brand pharmacy. So the next few months will look like the last few months from her perspective. The change happens when the final rule lands and the compounded path is closed. At that point she'll either get an email from Henry saying "we're switching you to brand semaglutide" or "your subscription is paused" or some variation. The good operators are going to handle the transition cleanly. The thinly-capitalized ones are going to be messy.

So what I told her: don't panic, but start the brand-pricing conversation now while you have time.

The brand math is more interesting than people realize. Yes, cash-pay Mounjaro from a US pharmacy without insurance is around $1000-1100 a month. But two things shift that. First, Lilly has a direct program (LillyDirect) that ships single-dose vials of Zepbound at meaningfully reduced cash pricing for patients without coverage. Second, if you have any commercial insurance at all, the prior-authorization process is worth doing, because once it goes through your monthly out-of-pocket can drop to $25 or so. The work is annoying but the math is huge.

Calibrate and Ro have built their whole business model around walking patients through that prior-auth process. Both will run a free insurance check before you sign up for anything. If you're paying $179 a month for compounded today, and after the rule lands you have to choose between $1000 cash for brand or $25 with insurance, the difference between you-do-the-paperwork-now and you-do-the-paperwork-after-your-supply-cuts-off is real money.

The other thing I told her, more carefully: the compounded supply she's been on is probably fine. Probably. The FDA's case for closing the 503B path isn't that everyone making compounded tirzepatide today is making bad product. It's that the regulatory foundation that allowed scale-compounding existed because of a shortage, the shortage is over, and so the foundation goes away. There's a separate quality concern too. Some partner pharmacies have had real problems. Mochi's main one (Aequita) got shut down in Washington State last March for sterile compounding violations. But that's not the headline reason for the rule.

What I would NOT do, even if I were on a tight budget: switch to research-chemical tirzepatide ordered online. The grey-market vendors have a quality distribution that genuinely scares me, and the customs enforcement environment is tightening. I keep meeting people in their thirties who think they're being clever and end up with a vial that may or may not actually contain what the COA says. The savings are real. The downside is the kind you don't want to find out about.

If she'd been considering starting from scratch today rather than asking about her existing supply, my answer would be different. I'd probably say wait six months. Foundayo (the new oral GLP-1, FDA-approved last month) is starting to roll out at $149 a month cash through Ro. Oral Wegovy 25mg is at the major UK pharmacies and trickling toward the US private market. The whole pricing landscape is going to look different by year-end.

But she's already on it. She's down 31 pounds. The harder thing to do is the unsexy paperwork: call her insurance, ask about Zepbound or Wegovy coverage, get a referral to whatever clinic her insurance prefers. Front-load the friction. She'll thank herself in three months.

That's what I told her. Take it as one person's read of the situation. Your specifics will vary.